Clinical trialNCT04486833RecruitingPhase 1/PHASE2Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

SponsorGenprex, Inc.Enrollment158Carcinoma, Non-Small Cell Lung

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark S. Berger, MD
Genprex, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Valkyrie Clinical Trials
Los Angeles, California, United States
David Berz, MD
Recruiting
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States
Robert M. Jotte, MD
Recruiting
Carle Cancer Institute
Urbana, Illinois, United States
Kendrith Rowland, MD
Recruiting
Markey Cancer Center
Lexington, Kentucky, United States
Zhonglin Hao, MD
Recruiting
Maryland Oncology Hematology
Rockville, Maryland, United States
John M. Wallmark, MD
Recruiting
the Valley Hospital - Luckow Pavilion
Paramus, New Jersey, United States
Eli D. Kirshner, MD
Recruiting
Gabrail Cancer Center Research
Canton, Ohio, United States
Nashat Gabrail, MD
Recruiting
Millennium Oncology
Houston, Texas, United States
Terminated
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander I. Spira, MD
Recruiting
Virginia Oncology Associates
Norfolk, Virginia, United States
Boon Kok, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Platinum-Based ChemotherapyOsimertinib →Quaratusugene ozeplasmid →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Sept 2021
Primary completion: 31 Mar 2028
Completion: 31 Mar 2029
Last update posted: 21 Jan 2026
Registered enrollment: 158
Registry id: NCT04486833

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.